Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $8.0, a ...

Shares of Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) are trading higher after the company, in collaboration with MIT, ...

Powered by Recursion's NVIDIA supercomputer for its training and validation, this next-generation AI model achieves best-in-class accuracy in jointly modeling complex structures and binding affinities ...

In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes through) become one company, combining Recursion’s expertise in biology with Exscientia’s focus on chemistry.

Investors in Recursion Pharmaceuticals Inc (Symbol: RXRX) saw new options begin trading today, for the July 25th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Binary News Network is a Content Syndication Platform that allows businesses or proprietary newswires to bring visibility to their content by syndicating it to premium, high-visibility networks ...